Published in Gene Therapy Weekly, March 15th, 2001
INGN 241 is currently in Phase I clinical development for the treatment of solid tumors.
Elizabeth Grimm, PhD, Ashbel Smith Professor in the Departments of Tumor Biology and Surgical Oncology at The University of Texas M.D. Anderson Cancer Center, and principal investigator of the study, presented these data at the Fifth World Conference on Melanoma, sponsored by the World Health Organization.
The preclinical study showed that INGN 241 caused growth arrest and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.